Ipamorelin for Fat Loss: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
Fat loss on Ipamorelin tracks the same mechanism as CJC-1295 fat loss: elevated GH and IGF-1 support lipolysis and lean-tissue preservation during a calorie deficit. The peptide does not directly suppress appetite or alter glucose metabolism the way GLP-1 analogs do. It supports the body composition environment that an active deficit creates. Ipamorelin alone is rarely used for fat loss; the canonical fat-loss GH protocol stacks Ipamorelin with CJC-1295 for the amplified GH pulse, and sometimes adds AOD-9604 for the dedicated lipolysis signaling.
The clinical pattern in user reports is consistent with the mechanism. Body recomposition over 8 to 12 weeks on a moderate calorie deficit plus consistent training. Less fat. Maintained or slightly grown lean tissue, particularly in men past 35 whose natural recomposition response has slowed. Anecdotally, users report the recomposition effect (mirror change, body fat percentage drop) is more visible than the scale weight change.
Used by many in the recovery / biohacking space alongside the diet and training work that drives the deficit. The peptide does not replace the deficit; it directs how the body partitions the deficit between fat loss and lean-tissue retention. Run this as a tactical, legal performance layer in a structured cutting block, not as a standalone fat-loss tool. For raw fat-loss firepower, GLP-1 analogs deliver more direct results, with their own trade-offs.
Dose for fat loss
100 to 200 mcg subcutaneous per injection, 2 to 3 times daily. Pre-training timing aligns with the lipolytic window during exercise. Pre-sleep dosing supports overnight fat oxidation. Stack with CJC-1295 (no-DAC at the same dose per injection, or with-DAC at 1 to 2 mg weekly) for the canonical fat-loss GH stack. AOD-9604 at 300 mcg pre-training can be added for dedicated lipolysis signaling.
Cycle length
8 to 12 weeks aligned with a structured calorie deficit and training block. Running Ipamorelin without a paired deficit does not deliver fat loss. Cycle off 4 to 6 weeks before another run.
Stack pairings
Commonly stacked with CJC-1295 and AOD-9604.
Expected timeline
Week 1–3: training recovery improves, hunger increases (ghrelin-receptor binding does this). Scale weight typically does not move dramatically in this window. Week 4–8: body composition shifts become visible. Lean tissue maintains or grows slightly even at calorie deficit; fat loss progresses faster than diet alone would predict. Week 8–12: cumulative recomp effect lands. Mirror change beats scale change.
Common mistakes
- Treating Ipamorelin as a fat-loss drug rather than a recomp support tool. The peptide supports lean-tissue preservation during a deficit; it does not replace the deficit. No deficit, no fat loss.
- Running Ipamorelin alone for fat loss without CJC-1295. The combined GH pulse from the stack consistently outperforms either alone. The fat-loss-tier protocols use both.
- Stacking with aggressive cutting diet without managing hunger. Ghrelin-receptor binding elevates appetite. A diet already at the white-knuckle adherence point may get worse before it gets better.
- Expecting GLP-1-level fat loss. Different mechanism, different outcomes. Ipamorelin is a recomp tool; GLP-1s are appetite-and-metabolism tools. For raw fat loss firepower, GLP-1s win.